Guardant Health Total Assets 2017-2021 | GH

Guardant Health total assets from 2017 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
  • Guardant Health total assets for the quarter ending September 30, 2021 were $2.226B, a 76.33% increase year-over-year.
  • Guardant Health total assets for 2020 were $2.272B, a 136.02% increase from 2019.
  • Guardant Health total assets for 2019 were $0.963B, a 63.86% increase from 2018.
  • Guardant Health total assets for 2018 were $0.587B, a 71.29% increase from 2017.
Guardant Health Annual Total Assets
(Millions of US $)
2020 $2,272
2019 $963
2018 $587
2017 $343
2016 $0
Guardant Health Quarterly Total Assets
(Millions of US $)
2021-09-30 $2,226
2021-06-30 $2,292
2021-03-31 $2,347
2020-12-31 $2,272
2020-09-30 $1,262
2020-06-30 $1,278
2020-03-31 $948
2019-12-31 $963
2019-09-30 $948
2019-06-30 $940
2019-03-31 $579
2018-12-31 $587
2018-09-30 $345
2018-06-30 $0
2018-03-31 $0
2017-12-31 $0
2017-09-30 $0
2016-12-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $9.928B $0.287B
Guardant Health Inc. is a precision oncology company. It focuses on conquer cancer through use of proprietary blood tests, vast data sets and advanced analytics. The company's Guardant Health Oncology Platform is designed for clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. It launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2. Guardant Health Inc. is based in REDWOOD CITY, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $121.969B 7.71
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.359B 20.93
Biohaven Pharmaceutical Holding (BHVN) United States $7.214B 0.00
Arcus Biosciences (RCUS) United States $3.030B 0.00
Emergent Biosolutions (EBS) United States $2.347B 8.44
ADC Therapeutics SA (ADCT) Switzerland $1.505B 0.00
Myovant Sciences (MYOV) United Kingdom $1.429B 0.00
Zymeworks (ZYME) Canada $0.942B 0.00
Ambrx Biopharma (AMAM) United States $0.366B 0.00
SQZ Biotechnologies (SQZ) United States $0.345B 0.00
Enzo Biochem (ENZ) United States $0.164B 16.09